Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03094052 · ClinicalTrials.gov registry record · Phase 2
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03094052 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 11 participants.
The verdict
NCT03094052, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.
Interventions
- DRUG Neratinib
- BIOLOGICAL Trastuzumab
- DRUG Loperamide
- DRUG Crofelemer
- DRUG Diphenoxylate/Atropine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-10-09 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03094052
The ClinicalTrials.gov registry entry for NCT03094052 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Neratinib is the first listed.
NCT03094052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03094052 about?
NCT03094052 is a clinical study titled "Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib". This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells,...
What is the current status of trial NCT03094052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-10-09. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT03094052?
The interventions under investigation include: Neratinib (DRUG), Trastuzumab (BIOLOGICAL), Loperamide (DRUG), Crofelemer (DRUG), Diphenoxylate/Atropine (DRUG).
Who is sponsoring clinical trial NCT03094052?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.